Neutralisation of elevated pro-survival BCL-2 family members has demonstrable clinical impact in cancer; venetoclax (ABT199) is a BCL-2-specific BH3-mimetic that has single-agent and combinatorial efficacy in some types of lymphoma and BH3-mimetic drugs are now in clinical trials for a range of cancers [5–8]. The gene discussed is BCL2; the disease is lymphoma.